Key result
Intradermal injection of leukotriene B4 (LTB4) acts as a mediator of vascular permeability, an effect observed only in the presence of a vasodilator such as PGE2.
Why the study?
Does intradermal injection of LTB4 increase vascular permeability in animal models?
Does intradermal injection of LTB4 increase vascular permeability in animal models?
LTB4 is a mediator of vascular permeability, but this effect is only observed in the presence of a vasodilator such as PGE2.
LTB4 permeability effects require vasodilators in animals; leaves open its role in human inflammatory edema.
1 Intradermal injection of leukotriene B4 (LTB4) or prostaglandin E2 (PGE2), 1 to 100 ng per skin site produced little or no change in plasma exudation in the rabbit, guinea-pig and rat. 2 Intradermal injection of LTB4 or PGE2 together with bradykinin (500 ng) resulted in a significant potentiation of the plasma exudation produced by bradykinin alone in the rabbit and guinea-pig. 4 LTB4 (1 to 10 ng) had no effect on blood flow in the rabbit skin, in contrast to PGE2 which was a potent vasodilator in this species. 5 It is concluded that LTB4 is a mediator of vascular permeability and that this effect can only be observed in the presence of a vasodilator such as PGE2.
No takes yet. Share an insight, caveat, or question.
Bray et al. (1981) studied this question. Intradermal injection of leukotriene B4 (LTB4) or prostaglandin E2 (PGE2) vs. Bradykinin alone was evaluated on Plasma exudation and blood flow. Intradermal injection of leukotriene B4 (LTB4) acts as a mediator of vascular permeability, an effect observed only in the presence of a vasodilator such as PGE2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: